Missouri Attorney General Expands Legal Action Against Mail-Order Abortion Pills
On Thursday, Missouri Attorney General Katherine Hannaway announced an expansion of the state’s legal efforts against mail-order abortion pills, specifically targeting the new generic version of mifepristone. Hannaway argues that these medications are leading to serious hospitalizations due to “life-threatening complications” and are entering the market without necessary medical safeguards.
The lawsuit takes aim at the Food and Drug Administration’s (FDA) approval from September 30, which greenlit the generic mifepristone from Evita Solutions. It contends that the risks associated with the drug are well-documented and are exacerbated by ongoing research.
According to the suit, the manufacturers are taking advantage of “weakened safety standards,” which were originally created to identify dangerous conditions, such as ectopic pregnancies, that should be detected through in-person medical evaluations.
Hannaway expressed concern, stating, “Mifepristone is sending women to the hospital with life-threatening complications, yet drug companies continue to push new versions of mifepristone onto the market without basic medical safeguards in place.” She emphasized that mail-order abortion pills pose significant dangers if taken without proper medical oversight.
The lawsuit is a response to what the states of Missouri, Kansas, and Idaho view as the FDA’s erosion of critical safety protections related to mifepristone. Historically, federal law has prohibited the mailing of abortion pills, but various distributors and telehealth services have managed to establish a system that delivers these medications nationwide, often without requiring an in-person consultation or follow-up care.
Missouri is now seeking a court order to halt new approvals of generic versions, restore pre-2016 safety measures necessitating in-person medical assessments, and prevent drug companies from mailing abortion medications in violation of federal laws.
Hannaway pointed to the drug’s warning label, noting that approximately 1 in 25 women who use chemical abortion pills end up in emergency rooms due to complications like bleeding and infections, often aggravated when these drugs are mailed without medical supervision. “No thoughtful physician would call mifepristone ‘as safe as Tylenol,'” she asserted, arguing that such claims are misleading and dangerous.
The announcement follows increased pressure from Republican lawmakers on the FDA to bolster oversight regarding abortion drugs and restore safety standards that have been relaxed recently.
Sen. Josh Hawley, R-Missouri, called upon the FDA to reinstate safety measures, questioning the agency’s relationship with manufacturers like Evita Solutions, which is central to Hannaway’s case. Meanwhile, Sen. Bill Cassidy from Louisiana mentioned that they’ve sought clarification from the FDA regarding its approval processes but have yet to receive a response.
As of now, Evita Solutions has not replied to requests for comment. The ongoing discussion highlights the contentious nature of drug approvals and the safety of mail-order medical options.
